Terumo (OTCMKTS:TRUMY) vs. TriSalus Life Sciences (NASDAQ:TLSI) Critical Survey

TriSalus Life Sciences (NASDAQ:TLSI) and Terumo (OTCMKTS:TRUMY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of recent ratings for TriSalus Life Sciences and Terumo, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1	1	3	0	2.40
Terumo	0	0	0	0	0.00

TriSalus Life Sciences currently has a consensus target price of $11.00, indicating a potential upside of 60.35%. Given TriSalus Life Sciences’ stronger consensus rating and higher possible upside, research analysts clearly believe TriSalus Life Sciences is more favorable than Terumo.

Profitability

This table compares TriSalus Life Sciences and Terumo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-98.45%	N/A	-111.88%
Terumo	12.35%	9.39%	7.08%

Risk and Volatility

TriSalus Life Sciences has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Terumo has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

Insider & Institutional Ownership

2.6% of TriSalus Life Sciences shares are owned by institutional investors. 27.5% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares TriSalus Life Sciences and Terumo”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$29.43 million	11.65	-$30.05 million	($2.02)	-3.40
Terumo	$6.80 billion	3.16	$772.05 million	$0.60	24.17

Terumo has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Terumo, indicating that it is currently the more affordable of the two stocks.

Summary

Terumo beats TriSalus Life Sciences on 8 of the 14 factors compared between the two stocks.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

About Terumo

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.